---
figid: PMC4073973__cmar-6-279Fig5
figtitle: Anti-PD-1 blocks T-cell suppression
organisms:
- Homo sapiens
- Diaporthe sclerotioides
organisms_ner:
- Homo sapiens
pmcid: PMC4073973
filename: cmar-6-279Fig5.jpg
figlink: /pmc/articles/PMC4073973/figure/f5-cmar-6-279/
number: F5
caption: 'Anti-PD-1 blocks T-cell suppression. Blocking the PD-1–PD-L1 pathway by
  using either a PD-1 antibody or a PD-L1 antibody allows for T-lymphocytes to mount
  a robust immune response against tumor cells.Abbreviation: TCR, T-cell receptor.'
papertitle: 'Update on benefit of immunotherapy and targeted therapy in melanoma:
  the changing landscape.'
reftext: Neeharika Srivastava, et al. Cancer Manag Res. 2014;6:279-289.
year: '2014'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8702087
figid_alias: PMC4073973__F5
figtype: Figure
redirect_from: /figures/PMC4073973__F5
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4073973__cmar-6-279Fig5.html
  '@type': Dataset
  description: 'Anti-PD-1 blocks T-cell suppression. Blocking the PD-1–PD-L1 pathway
    by using either a PD-1 antibody or a PD-L1 antibody allows for T-lymphocytes to
    mount a robust immune response against tumor cells.Abbreviation: TCR, T-cell receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD80
  - CD28
  - CD86
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - CD274
  - PDCD1
  - RPL17
  - RPL17-C18orf32
---
